This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): SNS-032
Description: SNS-032 is a novel aminothiazole small molecule cell-cycle modulator that targets CDK2, CDK7 and CDK9, thus halting the uncontrolled cell divisioncharacteristic of cancer. Preclinical studies have shown that SNS-032 induces cell-cycle arrest and apoptosis across multiple cell lines.
Deal Structure: In April 2005, Sunesis Pharmaceuticals obtained worldwide development and commercialization rights to BMS-387032 (now SNS-032) from Bristol-Myers Squibb Company. Under the terms of the agreement, Bristol-Myers Squibb will receive an up-front equity stake of $8 million in Sunesis. Sunesis will make a series of additional milestone payments of up to $29 million in cash and equity based on the successful development and approval for the first indication and formulation of SNS-032. Additional development and commercialization milestones could total up to $49 million in cash and equity. Sunesis will also make royalty payments based on net sales. In return, Sunesis will receive an exclusive, worldwide license to SNS-032 and future CDK inhibitors derived from related intellectual property.
In December 2008, Sunesis notified BMS that it was terminating the license agreement for SNS-032.
Additional information available to subscribers only: